share_log

Clover Health | 8-K: Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance

Clover Health | 8-K: Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance

Clover Health | 8-K：三葉草健康公佈2024年第二季度財務業績；改善了全年強勁業績指引
美股SEC公告 ·  2024/08/06 04:12

Moomoo AI 已提取核心訊息

Clover Health achieved its first quarterly GAAP profit as a public company in Q2 2024, reporting net income of $7.2 million compared to a $28.9 million loss in Q2 2023. Insurance revenue grew 11% year-over-year to $349.9 million, driven by strong member retention. The company's Insurance MCR improved to 71.3% from 77.2% in the prior year quarter.Adjusted EBITDA increased significantly to $36.2 million from $9.9 million in Q2 2023, reflecting improved operational efficiency. The company's technology-centric approach through Clover Assistant continues to drive positive outcomes. Based on strong performance, Clover Health raised its full-year 2024 guidance, now expecting Insurance revenue of $1.35-1.375 billion and Adjusted EBITDA of $50-65 million.The company's recent Star Rating improvement to 3.5 Stars for the 2025 payment year, coupled with a healthy balance sheet position of $482.8 million in cash and investments, positions it well for continued growth and improved long-term profitability capacity.
Clover Health achieved its first quarterly GAAP profit as a public company in Q2 2024, reporting net income of $7.2 million compared to a $28.9 million loss in Q2 2023. Insurance revenue grew 11% year-over-year to $349.9 million, driven by strong member retention. The company's Insurance MCR improved to 71.3% from 77.2% in the prior year quarter.Adjusted EBITDA increased significantly to $36.2 million from $9.9 million in Q2 2023, reflecting improved operational efficiency. The company's technology-centric approach through Clover Assistant continues to drive positive outcomes. Based on strong performance, Clover Health raised its full-year 2024 guidance, now expecting Insurance revenue of $1.35-1.375 billion and Adjusted EBITDA of $50-65 million.The company's recent Star Rating improvement to 3.5 Stars for the 2025 payment year, coupled with a healthy balance sheet position of $482.8 million in cash and investments, positions it well for continued growth and improved long-term profitability capacity.
Clover Health在2024年第二季度實現了作爲上市公司的首個季度GAAP利潤，報告凈利潤爲720萬，相比於2023年第二季度的2890萬虧損。保險營業收入同比增長11%，達34990萬，得益於強勁的會員留存。公司的保險MCR從去年同期的77.2%改善至71.3%。經調整的EBITDA大幅增加至3620萬，相比2023年第二季度的990萬，反映了運營效率的提升。公司通過Clover Assistant採取的科技導向方法繼續推動積極的成果。基於強勁的表現，Clover Health提高了其2024年的全年指導，現在預計保險營業收入爲135-137.5億和經調整EBITDA爲5000-6500萬。公司最近的科創板評級提高至2025年支付年度的3.5科創板，加上48280萬的現金和投資的健康資產負債表位置，使它在持續增長和改善長期盈利能力方面處於良好位置。
Clover Health在2024年第二季度實現了作爲上市公司的首個季度GAAP利潤，報告凈利潤爲720萬，相比於2023年第二季度的2890萬虧損。保險營業收入同比增長11%，達34990萬，得益於強勁的會員留存。公司的保險MCR從去年同期的77.2%改善至71.3%。經調整的EBITDA大幅增加至3620萬，相比2023年第二季度的990萬，反映了運營效率的提升。公司通過Clover Assistant採取的科技導向方法繼續推動積極的成果。基於強勁的表現，Clover Health提高了其2024年的全年指導，現在預計保險營業收入爲135-137.5億和經調整EBITDA爲5000-6500萬。公司最近的科創板評級提高至2025年支付年度的3.5科創板，加上48280萬的現金和投資的健康資產負債表位置，使它在持續增長和改善長期盈利能力方面處於良好位置。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Oscar Health
    OSCR
    -- 13.460
    Molina Healthcare
    MOH
    -- 272.280
    哈門那
    HUM
    -- 253.830
    康西哥
    CNC
    -- 56.860
    NeueHealth
    NEUE
    -- 7.330
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    多家機構看多！中國資產將全面重估：你會如何布局？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家機構唱好中國資產。 🎙️討論： 1. Deepseek引爆中國資產上漲，後市你怎麼看？ 2. 多家中國企業1月表現提升，你更看好誰？ 展开
    中國的資產重估引發熱議：牛友們在買什麼？